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Background/aim: To investigate whether autonomic nervous system (ANS) hyperactivity may be a potential cause for the relationship
between lower urinary tract symptoms (LUTS) and erectile dysfunction (ED).
Materials and methods: Twenty-four patients were recruited for this study. Complete physical examinations, urine analysis,
uroflowmetry, and postvoid residual urine volume (PVRU) analysis were performed. The potential impact of some factors such as
hyperglycemia, obesity, and hyperlipidemia were analyzed. These values were correlated with the various symptom scores. We performed
an electromyographic and an electrocardiographic evaluation. The alterations after treatment with 2 different alpha-blockers were also
analyzed.
Results: The electromyographic and electrocardiographic assessments revealed a minimal increase in ANS activity and it did not change
significantly after treatment (P > 0.05). After treatment, maximum flow rate increased and PVRU decreased significantly (P < 0.001
and P < 0.001, respectively); total and free testosterone levels increased significantly (P = 0.0068 and P = 0.0071, respectively). There
was a statistically significant difference between the 2 treatment groups regarding the outcomes of the Danish Prostate Symptom Score
questionnaire (P = 0.047).
Conclusion: This current study suggested that the effect of ANS hyperactivity is not the fundamental factor underlying the relationship
between LUTS and ED.
Key words: Autonomic nervous system hyperactivity, benign prostatic hyperplasia, erectile dysfunction

1. Introduction
Lower urinary tract symptoms (LUTS) and erectile
dysfunction (ED) are highly prevalent in aging men (1,2).
A cross-sectional study evaluating the prevalence of LUTS
over the age of 40 years revealed that its prevalence in
elderly Turkish men is fairly high and increases with age
(3). Because the number of men with LUTS associated
with benign prostatic hyperplasia (BPH) and ED
continues to increase, it is important to understand this
disease complex. Both disorders have major impacts on
the quality of life and socioeconomic implications, and
both are projected to increase because of demographic
changes (4). The hypotheses that have been proposed to
understand the relationship between ED and LUTS are as
follows: 1) increased Rho-kinase activation (5), 2) nitric
oxide synthase (NOS)/nitric oxide (NO) level decrease or
alteration (6), 3) atherosclerosis affecting the pelvis (7),
* Correspondence: umul7@yahoo.com

and 4) autonomic nervous system (ANS) hyperactivity
(8). In a previous study, an association was shown between
autonomic neural input to the prostate and prostatic
growth in rats, such that the absence of autonomic neural
input resulted in regression of the gland (9). These findings
were supported by other animal studies using a strain
of rats (spontaneously hypertensive rats) that develop
increased autonomic activity, prostate hyperplasia, and
erectile dysfunction (8,10,11). The ANS hyperactivity
hypothesis has been further supported by epidemiologic
studies (12,13).
The aim of this clinical study was to evaluate this
association in detail in a consecutive series of men referred
to our out-patient clinic in a predetermined time period.
Our hypothesis was that ANS hyperactivity, especially
sympathetic nervous system overactivity, might be a
potential cause for the relationship between LUTS and
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sexual dysfunction. We analyzed the potential causes for
the relationship between LUTS associated with BPH and
ED and the effects of several variables (serum free and
total testosterone levels, blood lipids, blood glucose level,
calculations of the weight and waist), as well as the effect
of autonomic hyperactivity. The alterations after treatment
with 2 different alpha-blockers (tamsulosin, 0.4 mg/daily
and alfuzosin, 10 mg/daily) were also analyzed.
2. Materials and methods
2.1. Patients and study protocol
Twenty-four consecutive patients were recruited for
our study. The study was approved by the local ethics
committee and all of the patients gave informed consent.
The inclusion criteria for the study were men with moderate
or serious LUTS associated with BPH [they had an
International Prostate Symptom Score (IPSS) of >8], with
a large prostate as identified by digital rectal examination
and ED [International Index of Erectile Function-5 (IIEF5) score of <21]. The patients were divided into groups for
ED severity according to IIEF-5 score (mild, moderate,
severe). The exclusion criteria were: 1) any prior medical
or surgical intervention for BPH; 2) phenylephrine,
pseudoephedrine, imipramine, or anticholinergic or
cholinergic medication before or during the investigation;
3) any clinically significant renal or hepatic impairment or
serious cardiovascular disease; 4) any suspicion of prostate
cancer, either clinically or by prostate-specific antigen
(PSA) levels; 5) any known neurological diseases affecting
the central or peripheral nervous systems, such as multiple
sclerosis; 6) serious diabetes mellitus for a long period of
time with poor glycemic control, which may affect the
innervation of the prostate, penis, and the bladder by
peripheral neuropathy. Insulin resistance, without the
presence of overt diabetes mellitus, has also been shown to
impair the response to the alpha-blocker therapy in men
with BPH (14).
A complete physical examination, including digital
rectal examination, urine analysis, uroflowmetry, and
postvoid residual urine (PVRU) volume analysis for all
patients, was performed at baseline. Serum free and total
testosterone levels, and free and total PSA levels, were
measured for the baseline evaluation of ED and BPH. The
potential impacts of some factors frequently associated
with increased sympathetic activity, like hyperglycemia,
abdominal and total obesity, and hyperlipidemia, were
also analyzed by measurement of serum lipid levels, blood
glucose levels, and weight and waist calculations of the
patients. These values were correlated with the various
symptom scores, maximum flow rate (Qmax), and PVRU
volume.
Patients were informed about the importance of diet
and exercise on the sexual functions at baseline and at each
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visit. To evaluate the autonomic activity circumstances,
we performed an electromyographic assessment by
amplitude and latency measurements of genitofemoral and
peripheral nerves for assessment of local (genitourinary)
and peripheral ANS activity (Figure 1). Additionally, an
electrocardiographic evaluation was performed to assess
heart rate during rest and hyperventilation. The RR
intervals were calculated on the electrocardiogram, which
was performed during rest and hyperventilation to assess
the central ANS activity. Patients were also evaluated
by the IPSS, IIEF, Danish Prostate Symptom Score Sex
(DAN-PSSsex), and Aging Males’ Symptoms (AMS)
scale questionnaires. After baseline assessment, patients
were randomly divided into 2 different treatment groups
(tamsulosin, 0.4 mg/daily and alfuzosin, 10 mg/daily; 12
patients for each group). Patients were reassessed at the
third and sixth months from baseline for alterations after
treatment with alpha-blockers. At visits 2 and 3, we also
performed physical examinations and other laboratory
investigations.
2.2. Statistical analysis
Statistical analysis was performed using SPSS 16.0 for
Windows (SPSS Inc., Chicago, IL, USA). Data were
presented as mean ± standard deviation for continuous
variables. We used the chi-square test, Student’s t-test,

ground

S

R2
(Active and
reference elec.)

R1

S: Electric stimulation
R1: Upper extremity SSR record area
R2: Genitale SSR record area

Figure 1. Electromyographic assessment of peripheral and
genitofemoral nerves.
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repeated measures ANOVA, the Bonferroni test, and
covariation analysis. The alterations after treatment
were investigated by repeated measures ANOVA and
Bonferroni test. Covariation analyses especially revealed
the relationship between laboratory findings before and
after alpha-blocker treatment. Differences were considered
to be significant at P < 0.05.

(Table 2). Fasting blood glucose level was normal in all
patients initially.
After treatment with 2 different alpha-blockers,
of the objective data for LUTS, Qmax increased and
PVRU volume decreased significantly (P < 0.001 and
P < 0.001, respectively). The total and free testosterone
levels increased significantly (P = 0.0068 and P = 0.0071,
respectively). As all patients were informed about the
importance of low dietary lipid intake and exercise, serum
lipid levels of all patients showed a marginal decrease at
follow-up. We observed a similar change in weight and
waist circumference measurements at the second and
third visits (P > 0.05). The PSA levels did not change
significantly at follow-up and we did not determine any
clinical signs of prostate cancer in any patients during the
second or third visits.
The evaluation for ANS activity at baseline by
electromyographic assessment of peripheral and
genitofemoral nerves by amplitude and latency
measurements for local and peripheral responses revealed
a minimal activity increase in the sympathetic nervous
system. On reassessment after treatment with alpha-

3. Results
A total of 24 consecutive men with LUTS and sexual
dysfunction were recruited for our study. None of the
patients discontinued the treatment due to side effects
during the follow-up period. The mean follow-up
period was 7.2 (6–18) months. The demographic data
of the 2 treatment groups were comparable (Table 1).
Multivariate analysis revealed that there was an objective
negative correlation between increasing body weight and
waist measurements and erectile function (P < 0.001).
Furthermore, in the category of the objectively recorded
data for LUTS associated with BPH and ED, we observed
a negative correlation between free testosterone levels and
weight and waist circumference measurements (P = 0.02)
Table 1. Demographic data of the patients at baseline.
Age
(years)

IPSS
score

IIEF
score

Weight
(kg)

Waist
circumference
(cm)

Total PSA
level (ng/mL)

Qmax
(mL/sec)

PVRU
(mL)

Group 1
(alfuzosin)

57.4 ± 7.6

15.5 ± 4.4

14.3 ± 3.7

79 ± 11.6

99.5 ± 7.8

1.9 ± 1.5

12.4 ± 6

69.1 ± 67

Group 2
(tamsulosin)

57 ± 6.5

16.7 ± 4.7

14.1 ± 3.5

80.6 ± 8.4

99.6 ± 6.6

1.6 ± 1.3

13.7 ± 4.2

1.6 ± 43.4

Table 2. The changes in mean questionnaire scores and laboratory findings before and after alpha-blocker treatment.
Alfuzosin

Tamsulosin

Before treatment

3rd month

6th month

Before treatment

3rd month

6th month

Total testosterone (ng/mL)*

5.9

6

6.3

5.9

6.8

6.7

Free testosterone (ng/dL)*

7.5

9.2

11.7

9.5

10

11.3

Qmax (mL/s)*

12.4

13.3

14.7

13.7

15.8

16.7

PVRU (mL)*

69.1

44.1

18.3

51.6

25

8.3

IPSS score

15.5

12.5

10.4

16.7

13.9

12.6

DAN-PSSsex* score

2.6/1.7/1.1

2.3/1.8/1

1.5/1.5/0.9

2/1.8/1.3

1.5/1.5/1.1

1.8/1.5/1

IIEF score

14.3

15.8

17.6

15.1

17.4

18

AMS score

29.5

26.3

24.8

33.8

30.5

29.1

*: P < 0.05.
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blockers at the third and sixth months of treatment, there
was no significant alteration of ANS activity (Figure 2;
P > 0.05). Electrocardiographic assessment revealed a
minimal increase in sympathetic nervous system activity
at baseline, but this did not change significantly after
alpha-blocker treatment (Figure 3; P > 0.05).
Regarding the questionnaires, IPSS values were
negatively correlated with sexual function. At the baseline
assessment before treatment with alpha-blockers, in the
category of subjective variables for LUTS, multivariate
analysis revealed a negative correlation between IPSS and
IIEF scores (P < 0.01; Table 2). Two of the participants
had severe (group A), 14 had moderate (group B), and 8
had mild (group C) ED at baseline. After treatment with
alpha-blockers, IPSS decreased and IIEF scores increased
significantly (P < 0.05). The changes in IIEF scores were
similar in groups A, B, and C (P > 0.05). Severe LUTS
6
Before

5

After

4
3
2
1
0

Latence

Amp

Latence

Amp

Latence

Amp

H-SSR

H-SSR

F-SSR

F-SSR

G-SSR

G-SSR

H-SSR: Sympathetic skin responses from hand
F-SSR: Sympathetic skin responses from foot
G-SSR: Sympathetic skin responses from genitofemoral nerve

Figure 2. Latency (ms) and amplitude (mV) measurements of
peripheral and genitofemoral nerves for all patients before and
after alpha-blocker treatment.
30

%

25
20

Before
After

15
10
5
0

Rest-RRIV

HV-RRIV

Rest -RRIV: RR interval during rest
HV -RRIV: RR interval during hyperventilation

Figure 3. Cardiac RR interval changes of all patients before and
after alpha-blocker treatment.
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was also associated with high AMS scores (Table 2). After
treatment with alpha-blockers, the IPSS, DAN-PSSsex, and
AMS scale scores decreased and IIEF scores increased for
all patients. There was a statistically significant difference
between the 2 treatment groups regarding the outcomes of
the DAN-PSSsex questionnaire due to the side effects of
tamsulosin on ejaculatory function (P = 0.047).
4. Discussion
LUTS and ED are common and bothersome problems
in aging males. It has been proposed that there might
be a relationship between these clinical conditions. The
2 most important theories suggest that the relationship
might have a direct pathophysiological basis, perhaps
mediated by the sympathetic nervous system, or that the
relationship might be psychological, such that the bother
associated with urinary symptoms results in impaired
sexual function (15,16). ANS hyperactivity is one of the
hypotheses used to clarify the relation between LUTS and
ED. This current study demonstrated that there is not a
significant correlation among LUTS, sexual function, and
ANS activity.
The Multinational Survey of the Aging Male (MSAM7) (15), one of the largest population-based studies about
aging males, evaluated the association between LUTS
and male sexual dysfunction, and the effects of age and
other comorbidities on these conditions, in 12,815 men
in the United States and some European countries. The
results of this study strengthened the current data about
relationships between LUTS and sexual dysfunction in
men, independent of the effects of age, comorbidities,
and various habitual factors. In multivariate analyses
that controlled for age, medical comorbidities (diabetes,
hypertension, cardiac disease, and hypercholesterolemia),
tobacco use, alcohol consumption, age, and the severity
of LUTS were independent risk factors for both ED and
ejaculatory dysfunction. A population-based study derived
from a cross-sectional health survey demonstrated the high
prevalence of LUTS and ED and their association (13). In
this study, the potential impact of some factors frequently
associated with increased sympathetic activity, like
hyperglycemia, obesity, hypertension, and hyperlipidemia,
were also analyzed by measurement of serum lipid levels,
fasting glucose, body mass index, and blood pressure. Even
though LUTS and ED are often associated with each other,
total calorie intake, alcohol consumption, obesity, waist/
hip ratio, diastolic blood pressure, presence of diabetes,
and hypertension did not individually predict clinical
BPH. Some epidemiological studies suggested that there
may be a relationship between sympathetic overactivity
and LUTS severity (12,13). However, these studies did not
control for extrinsic factors that could potentially influence
ANS activity, except for the study evaluating the effect of

UMUL et al. / Turk J Med Sci
ANS activity on the relationship between LUTS and ED by
McVary et al. (16).
The assessment of sympathetic skin responses (SSRs)
is a sensitive measurement of autonomic activity. In
several reports, the effects of diabetes on autonomic
activity were specifically investigated by SSR (17,18).
The loss of potentials from the hand and/or foot is often
regarded as a pathological sign of autonomic-sympathetic
neuropathy. Earlier detection of sympathetic involvement
of autonomic neuropathy seems to be possible in 2 ways.
First, using SSRs can reveal the reduction of the amplitude
and changes in latency in the extremities (18). Changes in
latency and reduction of amplitudes have been recognized
as initial signs of autonomic-sympathetic neuropathy
(17–19). In the present work, we revealed that the genital
and peripheral SSRs are easily obtained from subjects with
LUTS and ED to assess the ANS activity. The assessment
of ANS activity by SSRs did not reveal a significant activity
increase in our cohort. One of the most fundamental
functions of the ANS in humans is the maintenance
of adequate heart rate during rest and activity. We
evaluated RR interval variation during deep breathing

and rest to exploit this main function of the ANS. This
electrocardiographic evaluation also did not suggest any
significant ANS activity increase in patients with LUTS
and ED. One of our limitations for the present study is the
small number of subjects for each treatment group. The
assessment of orthostatic control of vascular tone is also a
sensitive measure of overall autonomic activity (20). The
assessment of blood pressure as a considerable function
of ANS could also be correlated with other measurements
to evaluate ANS activity. Furthermore, this work only
included patients applying for medical treatment for LUTS
associated with BPH.
In conclusion, the current study suggested that the
effect of an increase in ANS activity is not the fundamental
factor underlying the relationship between LUTS and
ED. The other hypotheses used to clarify the association
between LUTS and ED, such as pelvic atherosclerosis,
alpha-adrenergic receptor imbalance, decrease of NOS/
NO in the endothelium, or increased Rho-kinase
activation, might be more significant pathophysiologic
mechanisms. There is a need for more prospective and
randomized controlled studies.
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